These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 15632476)

  • 21. Calcium channel blockers.
    Hurwitz CU
    CRNA; 1996 Feb; 7(1):29-32. PubMed ID: 8680353
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Interaction of 1,4-dihydropyridines with ion channels].
    Veizerová L; Svetlík J; Kettmann V
    Ceska Slov Farm; 2008 Apr; 57(2):58-62. PubMed ID: 18578414
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Calcium channel blockers in myocardial and cerebral ischemia: a clinician's review from bench to bedside.
    Borger MA; Weisel RD
    Can J Cardiol; 1999 Mar; 15(3):333-40. PubMed ID: 10202197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Serial review No.12 Calcium antagonist-improvement in the study of basic and clinical research-Calcium and arrhythmia].
    Atarashi H
    Clin Calcium; 2004 Mar; 14(3):454-6. PubMed ID: 15577007
    [No Abstract]   [Full Text] [Related]  

  • 25. Linking calcium-channel isoforms to potential therapies.
    Belardetti F; Zamponi GW
    Curr Opin Investig Drugs; 2008 Jul; 9(7):707-15. PubMed ID: 18600576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Calcium antagonists--determination of current status and therapeutic significance].
    Regenthal R; Voigt H; Preiss R
    Z Gesamte Inn Med; 1992 Dec; 47(12):573-82. PubMed ID: 1283652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, and evaluation of a novel 4-aminomethyl-4-fluoropiperidine as a T-type Ca2+ channel antagonist.
    Shipe WD; Barrow JC; Yang ZQ; Lindsley CW; Yang FV; Schlegel KA; Shu Y; Rittle KE; Bock MG; Hartman GD; Tang C; Ballard JE; Kuo Y; Adarayan ED; Prueksaritanont T; Zrada MM; Uebele VN; Nuss CE; Connolly TM; Doran SM; Fox SV; Kraus RL; Marino MJ; Graufelds VK; Vargas HM; Bunting PB; Hasbun-Manning M; Evans RM; Koblan KS; Renger JJ
    J Med Chem; 2008 Jul; 51(13):3692-5. PubMed ID: 18540666
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium channel antagonists: clinical uses--past, present and future.
    Triggle DJ
    Biochem Pharmacol; 2007 Jun; 74(1):1-9. PubMed ID: 17276408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Calcium channel blockers. Review and attempt at classification].
    van Zwieten PA; Timmermans PB
    Rev Esp Cardiol; 1984; 37(5):322-9. PubMed ID: 6387828
    [No Abstract]   [Full Text] [Related]  

  • 30. [Large scale clinical trials of calcium channel blockers on the prevention of cardiovascular diseases].
    Shimamoto K
    Clin Calcium; 2005 Oct; 15(10):1609-14. PubMed ID: 16199905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Nimotop: clinical spectrum].
    Shirokov EA; Denishchuk IS; Polkhovskiĭ AA
    Klin Med (Mosk); 1998; 76(5):37-40. PubMed ID: 9644935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of an L- and N-type calcium channel blocker in hypertensive patients with neurovascular compression of the rostral ventrolateral medulla.
    Aota Y; Morimoto S; Sakuma T; Morita T; Jo F; Takahashi N; Maehara M; Ikeda K; Sawada S; Iwasaka T
    Hypertens Res; 2009 Aug; 32(8):700-5. PubMed ID: 19521420
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spontaneous muscle action potentials are blocked by N-type and P/Q-calcium channels blockers in the rat spinal cord-muscle co-culture system.
    Taguchi K; Shiina M; Shibata K; Utsunomiya I; Miyatake T
    Brain Res; 2005 Feb; 1034(1-2):62-70. PubMed ID: 15713260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Differentiated use of calcium antagonists. Current therapy of cardiovascular diseases].
    Internist (Berl); 1999 Oct; 40(10 Suppl Moderne):1-4. PubMed ID: 10549001
    [No Abstract]   [Full Text] [Related]  

  • 35. The ACTION study: nifedipine in patients with symptomatic stable angina and hypertension.
    Sierra C; Coca A
    Expert Rev Cardiovasc Ther; 2008 Sep; 6(8):1055-62. PubMed ID: 18793108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cilnidipine inhibits the sympathetic nerve activity and improves baroreflex sensitivity in patients with hypertension.
    Kishi T; Hirooka Y; Konno S; Sunagawa K
    Clin Exp Hypertens; 2009 May; 31(3):241-9. PubMed ID: 19387900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The newly developed calcium antagonist, azelnidipine, increases drain volume in continuous ambulatory peritoneal dialysis patients.
    Suzuki H; Inoue T; Kobayashi K; Shoda J; Nakamoto H
    Adv Perit Dial; 2006; 22():18-23. PubMed ID: 16983932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y; Hirooka Y; Sagara Y; Sunagawa K
    Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and SAR of selective T-type calcium channel antagonists containing a biaryl sulfonamide core.
    Hangeland JJ; Cheney DL; Friends TJ; Swartz S; Levesque PC; Rich AJ; Sun L; Bridal TR; Adam LP; Normandin DE; Murugesan N; Ewing WR
    Bioorg Med Chem Lett; 2008 Jan; 18(2):474-8. PubMed ID: 18160281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Calcium blockers and their their present application].
    Brzósko S; Hryszko T; Małyszko J; Myśliwiec M
    Przegl Lek; 1999; 56(9):592-8. PubMed ID: 10695366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.